Biocon Biologics Secures USFDA Nod for Groundbreaking Diabetes Treatment
Biocon Biologics has received USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog Insulin Aspart for diabetes treatment. Intended to improve glycemic control in individuals with diabetes mellitus, Kirsty marks Biocon's expansion in the biosimilar insulin market. It is already available in Europe and Canada.
- Country:
- India
Biocon Biologics announced a significant breakthrough on Wednesday, securing approval from the United States Food and Drug Administration (USFDA) for its diabetes medication, Kirsty.
This approval makes Kirsty the first and only interchangeable biosimilar to NovoLog (Insulin Aspart), designed to enhance glycemic management for adults and children with diabetes mellitus.
Now part of Biocon Biologics' expanding insulin biosimilar portfolio, Kirsty is available globally, having reached markets in Europe and Canada in 2022.
(With inputs from agencies.)
Advertisement
ALSO READ
AI to Accelerate Medicine Access in NZ: Seymour Pushes for Faster Drug Approvals
Health Rounds: 3D printed insulin-producing cells show promise for type 1 diabetes in lab tests
Telangana CM's Strategic Delhi Visit: Seeking Funds and Approvals
Health Sector Developments: Trump’s Bill, Major Mergers, and FDA Approvals
Google News